Unicycive Therapeutics, Inc. 8-K Filing

FAQ

Filing Documents

• ea0285174-8k_unicycive.htm (8-K) — 33KB
• 0001213900-26-040179.txt ( ) — 195KB
• uncy-20260406.xsd (EX-101.SCH) — 3KB
• uncy-20260406_lab.xml (EX-101.LAB) — 33KB
• uncy-20260406_pre.xml (EX-101.PRE) — 22KB
• ea0285174-8k_unicycive_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2026 Unicycive Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40582 81-3638692 (State or other jurisdiction of (Commission File Number) IRS Employer incorporation or organization) Identification No.) 1975 W. El Camino Real , Suite 204 Mountain View , CA 94040 (Address of principal executive offices) Registrant's telephone number, including area code: (650) 351-4495 (Former name or former address, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class: Trading Symbol(s) Name of each exchange on which registered: Common Stock UNCY Nasdaq Capital Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On April 6, 2026, Gaurav Aggarwal, a director of Unicycive Therapeutics, Inc. (the "Company"), resigned from the Board of Directors of the Company. Dr. Aggarwal's resignation was not a result of any disagreement with the Company or its management or Board on any matter related to the Company's operations, policies, or practices. The Company expressed its gratitude to Dr. Aggarwal for serving on the Unicycive Board of Directors. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 6, 2026 UNICYCIVE THERAPEUTICS, INC. By: /s/ Shalabh Gupta Shalabh Gupta Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR